Biomia is a synthetic biology company that engineers nature-inspired small molecule therapeutics to address the global crisis of CNS disorders. Utilizing a proprietary platform that combines AI-driven discovery with yeast-based biomanufacturing, Biomia optimizes and scales novel drug candidates for conditions such as chronic pain, schizophrenia, and opioid use disorder. The company is positioned to lead in the development of safe and effective CNS therapeutics, with a strong pipeline of compounds and a proven team of industry professionals. Their innovative approach aims to overcome the limitations of current therapeutics, which often leave symptoms untreated and can lead to severe side effects.

Lyngby, Denmark

Biomia

BlueYard invests in founders with transforming ideas that decentralize markets, empower users and liberate data

BY Capital Management GmbH

BlueYard Capital

Tell us about your professional DNA to get discovered by any company in our network with opportunities relevant to your career goals.

Leverage our network to build your career.

#### Hello,
In 5 quick steps, tell us about the type of opportunities you'd be interested in next. We'll use this information to connect you to relevant opportunities in the BlueYard Capital network as they come up. You can always update this information later.

As our companies grow, they look to us to help them find the best talent.

Signal that you'd be interested in working with a BlueYard Capital company to help us put the right opportunities at great companies on your radar. The choice to pursue a new career move is then up to you.

Explore open positions at BlueYard portfolio companies

Is this your company?